A Multicenter, Randomized, Double-blind, Vehicle-controlled, Phase 3 Efficacy and Safety Study of Patidegib Gel 2% for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects with Gorlin Syndrome
Objective
Primary Objective: To assess the efficacy of Patidegib Gel 2% when applied twice daily to the face of subjects with Gorlin syndrome.
Secondary Objective: To assess the safety and tolerability of Patidegib Gel 2% in subjects treated twice daily for 12 months
